Class summary at a glance.

Every drug in the Prostaglandin Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 15tracked in Part D
CY24 Part D spend: $1.29Bcombined across class
Total Rx claims: 19.4M5.7M unique beneficiaries
Generic mfrs (active): 40across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Bimatoprost

Brand: DURYSTA · 2.2M Part D claims (CY24) · 643K beneficiaries · First FDA approval: 2009-01-26

9 generic mfrs 1 plans require PA

Low NADAC$7.19

→

Avg plan cost$24.98

Part D spend $969.1M 3× spread, current vs floor

Class share

75%

of class CY24 spend

View profile →

Latanoprost

Brand: XALATAN · 16.6M Part D claims (CY24) · 4.9M beneficiaries · First FDA approval: 2010-11-15

8 generic mfrs 0 plans require PA

Low NADAC$1.20

→

Avg plan cost$12.26

Part D spend $204.7M 10× spread, current vs floor

Class share

16%

of class CY24 spend

View profile →

Travoprost

Brand: Travatan Z · 732K Part D claims (CY24) · 220K beneficiaries · First FDA approval: 2006-10-20

7 generic mfrs 0 plans require PA

Low NADAC$9.29

→

Avg plan cost$30.91

Part D spend $120.3M 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Alprostadil

Brand: Caverject · 12 Part D claims (CY24) · First FDA approval: 1981-10-16

2 generic mfrs

Low NADAC$82.49

→

Avg plan cost$152.13

Part D spend $10693 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Carboprost Tromethamine

Brand: Hemabate · — Part D claims (CY24) · First FDA approval: 1979-01-09

11 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Dinoprostone

Brand: CERVIDIL · — Part D claims (CY24) · First FDA approval: 1992-12-09

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Latanoprost Ophthalmic Solution

Brand: IYUZEH · — Part D claims (CY24) · First FDA approval: 2023-07-14

Brand-only (no generics)

Low NADAC$10.12

→

Avg plan cost$10.12

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Netarsudil and Latanoprost Ophthalmic Solution,

Brand: Rocklatan · — Part D claims (CY24) · First FDA approval: 2019-03-12

Brand-only (no generics) 2 plans require PA

Low NADAC$139.64

→

Avg plan cost$139.64

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Tafluprost

Brand: ZIOPTAN · — Part D claims (CY24) · First FDA approval: 2022-10-28

3 generic mfrs 0 plans require PA

Low NADAC$2.96

→

Avg plan cost$4.34

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Tafluprost Opthalmic

Brand: tafluprost · — Part D claims (CY24) · First FDA approval: 2022-11-18

Brand-only (no generics) 1 plans require PA

Low NADAC$2.96

→

Avg plan cost$2.96

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Travoprost (Isomer Free)

Brand: Travoprost · — Part D claims (CY24) · First FDA approval: 2024-10-10

Brand-only (no generics)

Low NADAC$9.29

→

Avg plan cost$9.77

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Travoprost Intracameral

Brand: iDose TR · — Part D claims (CY24) · First FDA approval: 2023-12-13

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Travoprost Ophthalmic

— Part D claims (CY24) · First FDA approval: 2025-12-17

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Travoprost Ophthalmic Solution

— Part D claims (CY24) · First FDA approval: 2021-04-15

Brand-only (no generics) 1 plans require PA

Low NADAC$9.29

→

Avg plan cost$9.77

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Travoprost Ophthalmic Solution Usp,

— Part D claims (CY24) · First FDA approval: 2019-12-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.